Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis ...Middle East

CHENGDU, China, June 2, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral...

Hence then, the article about keymed biosciences announces long term efficacy and safety data from a phase iii clinical trial of stapokibart for the treatment of moderate to severe atopic dermatitis was published today ( Monday 03/06/2024 - 04:17 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• 2 found dead after family disturbance reported in Concord
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor